Antiglaucoma EP2 Agonists: A long road that led somewhere

David F. Woodward, Jenny W. Wang, W. Daniel Stamer, E. Lütjen-Drecoll, Achim H.P. Krauss, Carol B. Toris

Research output: Contribution to journalReview article


For >2 decades, EP2 agonists have been the subject of antiglaucoma research and development by scientists in industry and academia around the world. The road has led to the recent approval of the first drug of this class. This article reviews the development of EP2 agonists from conception to clinical approval, discussing pharmacology, structure, biodistribution, therapeutics, and drug delivery. An extensive list of source references is provided for the reader's benefit.

Original languageEnglish (US)
Pages (from-to)469-474
Number of pages6
JournalJournal of Ocular Pharmacology and Therapeutics
Issue number9
StatePublished - Nov 2019



  • EP agonists
  • drug delivery
  • glaucoma therapy

ASJC Scopus subject areas

  • Ophthalmology
  • Pharmacology
  • Pharmacology (medical)

Cite this

Woodward, D. F., Wang, J. W., Stamer, W. D., Lütjen-Drecoll, E., Krauss, A. H. P., & Toris, C. B. (2019). Antiglaucoma EP2 Agonists: A long road that led somewhere. Journal of Ocular Pharmacology and Therapeutics, 35(9), 469-474.